Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate Efficacy and Safety of HS-10374 for Mild-to-moderate Plaque Psoriasis
Sponsor: Hansoh BioMedical R&D Company
Summary
This study has been designed to explore the clinical efficacy and safety of HS-10374 in the treatment of mild-to-moderate plaque psoriasis.
Official title: A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase II Study to Evaluate Clinical Efficacy and Safety of HS-10374 in Adult Patients With Mild-to-moderate Plaque Psoriasis
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
305
Start Date
2025-04-09
Completion Date
2026-12-09
Last Updated
2025-04-13
Healthy Volunteers
No
Conditions
Interventions
HS-10374 6mg tablets
Administered orally QD for 12 weeks
HS-10374-matched placebo tablets
Administered orally QD for 12 weeks
Locations (1)
Shanghai Dermatology Hospital
Shanghai, Shanghai Municipality, China